Published in Cancer Res on November 15, 1987
Role of gamma interferon and tumor necrosis factor alpha in resistance to Salmonella typhimurium infection. Infect Immun (1992) 2.95
Gamma interferon cooperates with lipopolysaccharide to activate mouse splenic macrophages to an antihistoplasma state. Infect Immun (1993) 1.29
Involvement of tumor necrosis factor alpha in intracellular multiplication of Legionella pneumophila in human monocytes. Infect Immun (1993) 1.03
Regulation of murine macrophage function by IL-4: IL-4 and IFN-gamma differentially regulate macrophage tumoricidal activation. Immunology (1993) 0.97
Attenuation of acute graft-versus-host disease in the absence of the transcription factor RORγt. J Immunol (2012) 0.94
A model for cancer-suppressive inflammation. Oncoimmunology (2012) 0.85
Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice. Cancer Res (1969) 1.26
Specific inhibition of the enzymic decarboxylation of S-adenosylmethionine by methylglyoxal bis(guanylhydrazone) and related substances. Biochem J (1974) 1.15
Protective effects of coffee diterpenes against aflatoxin B1-induced genotoxicity: mechanisms in rat and human cells. Food Chem Toxicol (2001) 1.04
Cytochrome P450 expression and related metabolism in human buccal mucosa. Carcinogenesis (2001) 1.04
Prostaglandin modulation of development of cell-mediated immunity in culture. Nature (1980) 1.00
Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance. Int J Cancer (1996) 0.99
Modification of tumor regression by immunologic means. Cancer Res (1969) 0.99
Role of tumor necrosis factor in macrophage activation and tumoricidal activity. Cancer Res (1988) 0.97
Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alpha. Cancer Res (1992) 0.91
Cell population kinetics of fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse. Cancer Res (1978) 0.89
Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Res (1984) 0.89
Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages. Cancer Res (1989) 0.89
Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res (1992) 0.88
Ecto-5'-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin. Int J Cancer (1994) 0.88
Effects of anticancer drugs on the immune system in humans. Semin Oncol (1989) 0.88
Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res (1977) 0.88
Toxicological and antiproliferative effects of N6-(delta2-isopentenyl) adenosine, a natural component of mammalian transfer RNA. Cancer Res (1970) 0.87
Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Int J Cancer (2000) 0.87
Immunosuppressive effects of methylglyoxal-bis(guanylhydrazone) on mouse bone marrow and spleen cells and their antagonism by spermidine. Biochem Pharmacol (1978) 0.87
Biologic-response modifiers and adjuvant chemotherapy: consideration of selected preclinical investigations in relation to clinical potential. Recent Results Cancer Res (1982) 0.87
Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res (1986) 0.86
A novel tumor necrosis factor-alpha inhibitory protein, TIP-B1. Int J Immunopharmacol (2000) 0.85
Doxorubicin-induced DNA degradation in murine thymocytes. Mol Pharmacol (1994) 0.85
Modification of host antitumor defense mechanisms in mice by progressively growing tumor. Cancer Res (1989) 0.85
Selective modulation by alpha-difluoromethylornithine of T-lymphocyte and antibody-mediated cytotoxic responses to mouse tumor allografts. Cancer Res (1986) 0.84
Marginal transfer of ReoPro (Abciximab) compared with immunoglobulin G (F105), inulin and water in the perfused human placenta in vitro. Placenta (2003) 0.83
Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother (1998) 0.83
Expression, tissue distribution, and cellular localization of the antiapoptotic TIP-B1 protein. J Leukoc Biol (2001) 0.83
Fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse. Cancer Res (1975) 0.82
The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension. Int J Clin Pharmacol Ther (2009) 0.82
Cholesterol-lowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and minipigs. Lipids Health Dis (2004) 0.82
Effects of prostaglandins on the development of cell-mediated immunity in culture and on the cytolytic activity of in vivo-generated effector cells. Int J Immunopharmacol (1982) 0.81
Modulation of the development of cell-mediated immunity: possible role of the products of the cyclo-oxygenase and the lipoxygenase pathways of arachidonic acid metabolism. Int J Immunopharmacol (1982) 0.81
The clinical toxicity of anticancer drugs and its prediction. Semin Oncol (1977) 0.81
Adriamycin induced immunomodulation: dependence upon time of administration. Int J Immunopharmacol (1983) 0.81
Effect of splenectomy on the regression of transplantable tumors. Cancer Res (1968) 0.81
Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin. Cancer Res (1988) 0.81
Exenatide effects on statin pharmacokinetics and lipid response. Int J Clin Pharmacol Ther (2007) 0.80
Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunol Immunother (1996) 0.80
Antigenic differences between leukemia L1210 and a subline resistant to methylglyoxal-bis(guanylhydrazone). Cancer Res (1972) 0.80
Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int J Cancer (1995) 0.80
Plasma membrane as a site for chemotherapeutic intervention. Adv Enzyme Regul (1978) 0.80
Changes in cytosolic and membrane TNF inhibitory protein-B1 (TIP-B1) levels associated with protection from TNF-induced cytotoxicity. FASEB J (2001) 0.79
Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother (1995) 0.79
Toxic and patologic effects of 4,4'-diacetyl-diphenyl-urea-bis(guanylhydrazone), a new antileukemic agent. Cancer Res (1969) 0.79
Comparative study of the toxicologic effects of 7-deazaadenosine (tubercidin) and 7-deazainosine. Cancer Res (1969) 0.79
Comparison of adriamycin induced immunomodulation with that of the noncardiotoxic anthracycline 5-iminodaunorubicin. Int J Immunopharmacol (1988) 0.79
Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation. Int J Cancer (1998) 0.79
Lipopolysaccharide and splenic tumoricidal macrophage activation. J Leukoc Biol (1994) 0.79
Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas. Oncol Res (1993) 0.78
Murine splenic macrophage tumoricidal activation by cytokines. Exp Hematol (1995) 0.78
Plasma pharmacokinetics and biological activity of a human immunodeficiency virus type 1 neutralizing human monoclonal antibody, F105, in cynomolgus monkeys. J Immunother Emphasis Tumor Immunol (1994) 0.78
Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions. Cancer Immunol Immunother (1990) 0.78
Selective effects of Adriamycin on murine host defense systems. Immunol Rev (1982) 0.78
Evaluation of combination chemotherapy in vivo and in culture with l- -D-arabinofuranosylcytosine and 1-formylisoquinoline thiosemicarbazone. Cancer Res (1972) 0.78
Identification, characterization, and cloning of TIP-B1, a novel protein inhibitor of tumor necrosis factor-induced lysis. Cancer Res (1999) 0.78
Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay. Cancer Res (1975) 0.78
Polymyxin B-mediated lysis of tumor cells. Int Arch Allergy Immunol (1993) 0.78
The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigens. Int J Immunopharmacol (1983) 0.78
Induction of suppressor T cells in culture--I. Cell-cell interactions. Int J Immunopharmacol (1984) 0.78
Differences in the immunogenicity of leukemia L1210 sublines in DBA-2 mice. Cancer Res (1971) 0.77
Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. II. Increased expression of tumor-associated antigens on subline cells recognized by serologic and transplantation methods. J Natl Cancer Inst (1979) 0.77
Anticancer drugs plus cytokines: immunodulation based therapies of mouse tumors. Int J Immunopharmacol (2000) 0.77
Immunomodulating effects of anticancer drugs: the example of adriamycin. Transplant Proc (1984) 0.77
In vitro effects of 4-hydroxyperoxycyclophosphamide on human immunoregulatory T subset function. Methods Find Exp Clin Pharmacol (1987) 0.77
Selectivity of inhibition by anticancer agents of mouse spleen immune effector functions involved in responses to sheep erythrocytes. Cancer Res (1978) 0.77
Doxorubicin and cyclosporin A affect murine lymphoid cells expressing different antigenic determinants. Oncol Res (1995) 0.77
Suppression of hepatic lymphokine-activated killer cell induction by murine Kupffer cells and hepatocytes. Hepatology (1990) 0.77
Constitutive and inducible expression of drug metabolizing enzymes in cultured human keratinocytes. Br J Dermatol (1995) 0.77
Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study. Oncol Res (1994) 0.77
Augmentation of the development of immune responses of mice against allogeneic tumor cells after adriamycin treatment. Cancer Res (1981) 0.77
Reversal of the in vitro methotrexate suppression of cell-mediated immune response by folinic acid and thymidine plus hypoxanthine. Cancer Res (1980) 0.77